Understanding the Launch in GT Biopharma Inc (OTCMKTS:GTBP) Shares

Understanding the Launch in GT Biopharma Inc (OTCMKTS:GTBP) Shares

SHARE

Wednesday’s market action featured very little movement from the major indices, but we did see one truly remarkable move on the OTC: the launch in shares of GT Biopharma Inc (OTCMKTS:GTBP). The stock closed up about 80% on the day, powered by nearly 26x average volume. The move was in reaction to the company’s announcement that its Tri-Specific Killer Engager can apparently target HIV infected cells according to preclinical testing conducted at the University of Minnesota.

According to the release, in preclinical testing led by Drs. Jeffrey Miller, MD, Deputy Director Masonic Cancer Center and Timothy Schacker, MD, Medical School and Director, Program In HIV Medicine, the research team designed a series of Bi- and Tri- Specific killer-engager (BiKE and TriKE) constructs to direct Natural Killer cell antibody dependent cell-mediated cytotoxicity against an HIV infected target.

GT Biopharma Inc (OTCMKTS:GTBP) trumpets itself as a clinical stage biopharmaceutical company that focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms.

The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors.

It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness.

GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.

According to company materials, “GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology products based off our proprietary Tri-specific Killer Engager (TriKE), Tetra-specific Killer Engager (TetraKE) and bi-specific Antibody Drug Conjugate (ADC) technology platforms. Our TriKE and TetraKE platforms generate proprietary moieties designed to harness and enhance the cancer killing abilities of a patient’s own natural killer, or NK, cells. Once bound to a NK cell, our moieties are designed to enhance the NK cell and precisely direct it to one or more specifically-targeted proteins (tumor antigens) expressed on a specific type of cancer, ultimately resulting in the cancer cell’s death. TriKEs and TetraKEs are made up of recombinant fusion proteins, can be designed to target certain tumor antigens on hematologic malignancies, sarcomas or solid tumors and do not require patient-specific customization. They are designed to be dosed in a common outpatient setting similar to modern antibody therapeutics. Our Multi-Target Bispecific Drug Conjugate (MTBDC) platform can generate product candidates that are bi-specific, ligand-directed single-chain fusion proteins that, we believe, represent the next generation of antibody directed drug conjugate therapies.”

Find out when $GTBP reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, GTBP just announced its Tri-Specific Killer Engager can target HIV infected cells in University of Minnesota’s preclinical testing.

We’ve witnessed 69% during the past week in terms of shareholder gains in the name. Furthermore, the name has seen interest climb, with an increase in recent trading volume of just shy of 380% above its longer-run average levels. It pays to take note of this fact due to the relatively small float size in the stock (roughly 14M shares).

CEO, GT Biopharma, Inc., Anthony Cataldo stated, “According to the World Health Organization, there are over 36 million people currently infected with HIV. The current drugs available to HIV patients only treat the symptoms of HIV at a massive economic cost. They remain infected for the rest of their lives on theses drugs and at risk for serious infections and certain cancers, while still being infectious to others. The TriKE/BiKE represents the possibility of a cure.”

Now commanding a market cap of $29.54M, GTBP has virtually no cash on the books, which is balanced by about $14M in total current liabilities. One should also note that debt has been growing over recent quarters. The company is pre-revenue at this point. This may be a very interesting story and we will look forward to updating it again soon. Sign-up for continuing coverage on shares of $GTBP stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $GTBP, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter